118 related articles for article (PubMed ID: 27663590)
1. Prognostic Utility of a New mRNA Expression Signature of Gleason Score.
Sinnott JA; Peisch SF; Tyekucheva S; Gerke T; Lis R; Rider JR; Fiorentino M; Stampfer MJ; Mucci LA; Loda M; Penney KL
Clin Cancer Res; 2017 Jan; 23(1):81-87. PubMed ID: 27663590
[TBL] [Abstract][Full Text] [Related]
2. Epigenome-Wide Tumor DNA Methylation Profiling Identifies Novel Prognostic Biomarkers of Metastatic-Lethal Progression in Men Diagnosed with Clinically Localized Prostate Cancer.
Zhao S; Geybels MS; Leonardson A; Rubicz R; Kolb S; Yan Q; Klotzle B; Bibikova M; Hurtado-Coll A; Troyer D; Lance R; Lin DW; Wright JL; Ostrander EA; Fan JB; Feng Z; Stanford JL
Clin Cancer Res; 2017 Jan; 23(1):311-319. PubMed ID: 27358489
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive analysis of alternative splicing across multiple transcriptomic cohorts reveals prognostic signatures in prostate cancer.
Mou Z; Spencer J; McGrath JS; Harries LW
Hum Genomics; 2023 Nov; 17(1):97. PubMed ID: 37924098
[TBL] [Abstract][Full Text] [Related]
4. Point-Counterpoint: Grade Group 1 (Gleason Score 6) Prostate Cancer Should Be Renamed to Improve Public Health: Pathologists' Perspective.
Zhou M; Paner GP
J Urol; 2023 Jul; 210(1):23-25. PubMed ID: 37126310
[No Abstract] [Full Text] [Related]
5. Immunological signature.
Visan I
Nat Immunol; 2023 Nov; 24(11):1781. PubMed ID: 37845491
[No Abstract] [Full Text] [Related]
6. A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer.
McKay RR; Werner L; Mostaghel EA; Lis R; Voznesensky O; Zhang Z; Marck BT; Matsumoto AM; Domachevsky L; Zukotynski KA; Bhasin M; Bubley GJ; Montgomery B; Kantoff PW; Balk SP; Taplin ME
Clin Cancer Res; 2017 Feb; 23(4):935-945. PubMed ID: 27683182
[No Abstract] [Full Text] [Related]
7. Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis.
Zhao SG; Chang SL; Spratt DE; Erho N; Yu M; Ashab HA; Alshalalfa M; Speers C; Tomlins SA; Davicioni E; Dicker AP; Carroll PR; Cooperberg MR; Freedland SJ; Karnes RJ; Ross AE; Schaeffer EM; Den RB; Nguyen PL; Feng FY
Lancet Oncol; 2016 Nov; 17(11):1612-1620. PubMed ID: 27743920
[TBL] [Abstract][Full Text] [Related]
8. Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles.
Hoang DT; Iczkowski KA; Kilari D; See W; Nevalainen MT
Oncotarget; 2017 Jan; 8(2):3724-3745. PubMed ID: 27741508
[TBL] [Abstract][Full Text] [Related]
9. The Added Value of Circulating Tumor Cell Enumeration to Standard Markers in Assessing Prognosis in a Metastatic Castration-Resistant Prostate Cancer Population.
Heller G; Fizazi K; McCormack R; Molina A; MacLean D; Webb IJ; Saad F; de Bono JS; Scher HI
Clin Cancer Res; 2017 Apr; 23(8):1967-1973. PubMed ID: 27678453
[No Abstract] [Full Text] [Related]
10. Adjuvant radiation therapy is associated with better oncological outcome compared with salvage radiation therapy in patients with pN1 prostate cancer treated with radical prostatectomy.
Tilki D; Preisser F; Tennstedt P; Tober P; Mandel P; Schlomm T; Steuber T; Huland H; Schwarz R; Petersen C; Graefen M; Ahyai S
BJU Int; 2017 May; 119(5):717-723. PubMed ID: 27743493
[TBL] [Abstract][Full Text] [Related]
11. Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer.
Loeb S; Shin SS; Broyles DL; Wei JT; Sanda M; Klee G; Partin AW; Sokoll L; Chan DW; Bangma CH; van Schaik RHN; Slawin KM; Marks LS; Catalona WJ
BJU Int; 2017 Jul; 120(1):61-68. PubMed ID: 27743489
[TBL] [Abstract][Full Text] [Related]
12. Association Between Androgen Deprivation Therapy and Risk of Dementia.
Nead KT; Gaskin G; Chester C; Swisher-McClure S; Leeper NJ; Shah NH
JAMA Oncol; 2017 Jan; 3(1):49-55. PubMed ID: 27737437
[TBL] [Abstract][Full Text] [Related]
13. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients.
Del Re M; Biasco E; Crucitta S; Derosa L; Rofi E; Orlandini C; Miccoli M; Galli L; Falcone A; Jenster GW; van Schaik RH; Danesi R
Eur Urol; 2017 Apr; 71(4):680-687. PubMed ID: 27733296
[TBL] [Abstract][Full Text] [Related]
14. Recent progress and perspectives on prostate cancer biomarkers.
Hatakeyama S; Yoneyama T; Tobisawa Y; Ohyama C
Int J Clin Oncol; 2017 Apr; 22(2):214-221. PubMed ID: 27730440
[TBL] [Abstract][Full Text] [Related]
15. Understanding the role of new systemic agents in the treatment of prostate cancer.
Corfield J; Crozier J; Joshua AM; Bolton D; Lawrentschuk N
BJU Int; 2016 Oct; 118 Suppl 3():8-13. PubMed ID: 27709828
[TBL] [Abstract][Full Text] [Related]
16. Prostate Specific Antigen-Growth Curve Model to Predict High-Risk Prostate Cancer.
Shoaibi A; Rao GA; Cai B; Rawl J; Haddock KS; Hébert JR
Prostate; 2017 Feb; 77(2):173-184. PubMed ID: 27699819
[TBL] [Abstract][Full Text] [Related]
17. Stromal and epithelial transcriptional map of initiation progression and metastatic potential of human prostate cancer.
Tyekucheva S; Bowden M; Bango C; Giunchi F; Huang Y; Zhou C; Bondi A; Lis R; Van Hemelrijck M; Andrén O; Andersson SO; Watson RW; Pennington S; Finn SP; Martin NE; Stampfer MJ; Parmigiani G; Penney KL; Fiorentino M; Mucci LA; Loda M
Nat Commun; 2017 Sep; 8(1):420. PubMed ID: 28871082
[TBL] [Abstract][Full Text] [Related]
18. Molecular Signature to Risk-Stratify Prostate Cancer of Intermediate Risk.
Yin Y; Zhang Q; Zhang H; He Y; Huang J
Clin Cancer Res; 2017 Jan; 23(1):6-8. PubMed ID: 27803045
[TBL] [Abstract][Full Text] [Related]
19. Prospective study of Type 2 diabetes mellitus, anti-diabetic drugs and risk of prostate cancer.
Häggström C; Van Hemelrijck M; Zethelius B; Robinson D; Grundmark B; Holmberg L; Gudbjörnsdottir S; Garmo H; Stattin P
Int J Cancer; 2017 Feb; 140(3):611-617. PubMed ID: 27770555
[TBL] [Abstract][Full Text] [Related]
20. Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Kearns B; Pandor A; Stevenson M; Hamilton J; Chambers D; Clowes M; Graham J; Kumar MS
Pharmacoeconomics; 2017 Apr; 35(4):415-424. PubMed ID: 27770303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
